Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy

Inclusion Criteria: * 1.Patients with histologically confirmed advanced renal cell carcinoma including clear cell component and not available for surgery * 2.Previously Failed Or Are Intolerant To TKIs Therapy(such as sunitinib, Sorafenib) * 3.With measurable disease (using RECIST1.1) * 4.18-75years,ECOG PS:0-1,Life expectancy of more than 3 months * 5.Last TKIs Therapy≥4 weeks * 6.Main organs function is normal * 7.Signed and dated informed consent Exclusion Criteria: * 1.patients has many influence factors toward oral medications * 2.Known brain metastases * 3.patients with severe and failed to controlled diseases,including: suboptimal blood pressure control;suffering from myocardial ischemia or above grade I myocardial infarction, arrhythmias and Class I heart failure;activity or failure to control severe infections;liver disease such as cirrhosis, decompensated liver disease, chronic active hepatitis;poorly controlled diabetes (FBG)\>10mmol/L);urine protein≥++,etc. * 4.patients failed to heal wounds or fractures for Long-term * 5.patients occurred venous thromboembolic events within 6 months * 6.patients has HIV-positive or organ transplantation